REGENXBIO is a leading biotechnology company specializing in the development and commercialization of AAV gene therapy using its proprietary NAV® Technology Platform. The platform includes exclusive rights to over 100 novel AAV vectors aimed at transforming the lives of patients with severe diseases.
